Oppenheimer lowered the firm’s price target on Regeneron (REGN) to $800 from $900 and keeps an Outperform rating on the shares. Despite ongoing issues with co-pay assist, alongside biosimilar competition, branded Eylea revenues grew 2.5% quarter-over-quarter, while Eylea HD grew an “impressive” 28% quarter-over-quarter, the analyst tells investors. Uncertainties remain on the policy front, but given Eylea’s resilience, the firm is “more confident that this floor is real,” the analyst added in a reaction to Q2 earnings.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on REGN:
- Early notable gainers among liquid option names on August 1st
- Options Volatility and Implied Earnings Moves Today, August 01, 2025
- Regeneron narrows FY25 non-GAAP R&D view to $5.100B-$5.200B from $5.000B-$5.200B
- Regeneron reports Q2 non-GAAP EPS $12.89, consensus $8.43
- Trump posts letters calling on drug company CEOs to lower prices